

0.1379

Centers for Disease Control and Prevention

Date Received:

NIOSH IRB (HSRB)

06/30/2014 *10/16/15hc*



**Signature Page for Human Research Review  
Protocols and Related Documentation**

Anniversary Date: 11/01/2015

Use this signature page when submitting HRPO forms to your center-level Human Subjects Contact. When submitting materials with these forms, please consecutively number all pages, beginning with the protocol title page and followed by consent form(s) and ancillary documents. See *HRPO Guide: Overview* for further details. **NOTE: IRB (Institutional Review Board) refers to the NIOSH IRB-HSRB (National Institute for Occupational Safety and Health (NIOSH), Human Subjects Review Board (HSRB) of the CDC Human Research Protection Office (HRPO).**

**1 Protocol Identifiers**

CAN#: 2927ZKPX (optional)

Leave protocol ID blank if not yet assigned.

CDC Protocol ID: HSRB 12-DART-04XP Protocol Version Number: \_\_\_\_\_ Version Date: \_\_\_\_\_

Protocol Title:

INTERVENTIONS TO REDUCE SHOULDER MSDS IN OVERHEAD ASSEMBLY

Amendment Number (if applicable): \_\_\_\_\_

**2 Key CDC Personnel**

	Name and Degrees (First Name Last Name, Degrees)	User ID	CDC SEV #	CDC NC/Division
Primary Contact Phone Number (required)	<u>Brian D. Lowe, Ph.D.</u> <u>513-533-8161</u>	<u>bfl4</u>	<u>10556</u>	<u>NIOSH/DART</u>
Principal Investigator Phone Number (required)	<u>Brian D. Lowe, Ph.D.</u> <u>513-533-8161</u>	<u>bfl4</u>	<u>10556</u>	<u>NIOSH/DART</u>

SEV # is CDC's Scientific Ethics Verification Number. CDC NC/Division is the national center or equivalent and division or equivalent, or coordinating center or office if submitted at that level.

**3 Forms Submitted with this Signature Page**

Check all that apply in the appropriate column.

**IRB-Reviewed Protocols**

- 0.1250: Initial Review by IRB
- 0.1251: Continuing Review of Approved Protocol
- 0.1252: Review of Changes to Approved Protocol
- 0.1254: Incident Report
- 0.1254S: Supplemental Adverse Event Report
- 0.1253: End of Human Research Review
- 0.1370: CDC's Research Partners
- 0.1371: CDC Rely on a Non-CDC IRB
- 0.1372: Outside Institution Rely on a CDC IRB
- 0.1373: CDC Cover an Individual Investigator

**Exempted Protocols (All shaded will not apply here)**

- 0.1250X: Initial Review for Exemption
- 0.1251X: Continuing Review of Exempted Protocol
- 0.1252X: Review of Changes to Exempted Protocol
- 0.1253: End of Human Research Review
- 0.1370: CDC's Research Partners

**4 Signatures**


As principal investigator, I hereby accept responsibility for conducting this CDC-sponsored research project in an ethical manner, consistent with the policies and procedures contained in CDC's *Procedures for Protection of Human Research Participants*, and to abide by the principles outlined in federal policies for the protection of human subjects at 45 CFR part 46, 21 CFR part 50, and 21 CFR part 56.

Signature	Date Signed	Remarks
Principal CDC Investigator: <b>Brian D. Lowe -S</b> <small>Digitally signed by Brian D. Lowe -S DN: c=US, o=U.S. Government, ou=HHS, ou=CDC, ou=People cn=Brian D. Lowe -S, o.9.2342.19200300.100.1.1=1000081744 Date: 2015.10.07.13:58:29 -04'00'</small>	10/07/2015	

As a supervisor of the principal investigator, I hereby accept responsibility for ensuring that this CDC-sponsored research project is conducted in an ethical manner, consistent with the policies and procedures contained in CDC's *Procedures for Protection of Human Research Participants*, and to abide by the principles outlined in federal policies for the protection of human subjects at 45 CFR part 46, 21 CFR part 50, and 21 CFR part 56.

Signature	Date Signed	Remarks
Team Lead: <b>Stephen Hudock -S</b> <small>Digitally signed by Stephen Hudock -S DN: c=US, o=U.S. Government, ou=HHS, ou=CDC, ou=People cn=Stephen Hudock -S, o.9.2342.19200300.100.1.1=1001277359 Date: 2015.10.07.14:01:32 -04'00'</small>	10/07/2015	<input type="checkbox"/> PI is Team Lead
Branch Official (e.g., Chief or Senior Scientist): <b>Naomi G. Swanson -S</b> <small>Digitally signed by Naomi G. Swanson -S DN: c=US, o=U.S. Government, ou=HHS, ou=CDC, ou=People o.9.2342.19200300.100.1.1=1000937885, cn=Naomi G. Swanson -S Date: 2015.10.07.14:25:08 -04'00'</small>	10/07/2015	<input type="checkbox"/> PI is Branch Official
Division Official (e.g., Director or ADS): <b>Rashaun K. Roberts -S</b> <small>Digitally signed by Rashaun K. Roberts -S DN: c=US, o=U.S. Government, ou=HHS, ou=CDC, ou=People o.9.2342.19200300.100.1.1=1001197730, cn=Rashaun K. Roberts -S Date: 2015.10.13.22:45:02 -04'00'</small>	10/13/2015	<input type="checkbox"/> PI is Division Official

I concur that this CDC-sponsored research project is consistent with the policies and procedures contained in CDC's *Procedures for Protection of Human Research Participants* and with other applicable CDC and national center policies.

Signature	Date Signed	Remarks
/Chair NIOSH IRB-HSRB: 	10/29/2015	
Other Clearance Official: (e.g., Confidentiality Officer, Coordinating Center/Office Official)		

**THIS SECTION FOR CDC/NIOSH IRB-HSRB OFFICE USE ONLY:**

Expedited Review , Minimal Risk ; as provided for in 45CFR46.110.

(b) (1) category(s) 4, 6, 7

Approved Review  for one year, Renewal Date: 11-1-16

CDC 0.1250 cites Estimated Subject # is 125 Subject # to Date is 76

Approved/Amended Subject # is 125

**COMMENTS:**

Full/Convened Board Review Approved  Meeting Date Approval: \_\_\_\_\_

**APPROVED**

**5 Additional Comments**

**6 Reminder Regarding Other Regulatory Clearance Processes**

The principal investigator is responsible for obtaining other regulatory reviews as needed, which may include OMB clearance under the Paperwork Reduction Act (PRA) for federally sponsored information collections. Approval by or exemption from the IRB is unrelated to OMB clearance requirements under the PRA. For more information on whether your study requires clearance under PRA or other regulations, please consult the appropriate officials within your national center.



0.1251 Centers for Disease Control and Prevention

## Request for Continuing Review of IRB-Approved Protocol

Use this form to submit a protocol for continuing review by a CDC IRB (Ex. NIOSH IRB-HSRB) or a non-CDC IRB. [See 45 CFR 46.109(e).] See *HRPO Guide: IRB Review Cycle* for further details on how to complete this form.

### 1 Protocol Identifiers

CDC Protocol ID: HSRB 12-DART-04XP Protocol Version Number: \_\_\_\_\_ Version Date: \_\_\_\_\_

Protocol Title:

INTERVENTIONS TO REDUCE SHOULDER MSDS IN OVERHEAD ASSEMBLY

### 2 Key CDC Personnel

No change in key CDC personnel. When checked or not, please cite all CDC and NIOSH investigators.

	Name and Degrees (First Name Last Name, Degrees)	User ID	CDC SEV #	CDC NC/Division
Primary Contact (required)	<u>Brian D. Lowe</u>	<u>bfl4</u>	<u>10556</u>	<u>NIOSH/DART</u>
Principal Investigator (required)	<u>Brian D. Lowe</u>	<u>bfl4</u>	<u>10556</u>	<u>NIOSH/DART</u>
Investigator 2	<u>Stephen Hudock, Ph.D.</u>	<u>sxh5</u>	<u>19227</u>	<u>NIOSH/DART</u>
Investigator 3	<u>Steven Wurzelbacher, PhD</u>	<u>srw3</u>	<u>4169</u>	<u>NIOSH/DSHEFS</u>
Investigator 4	<u>Peter Shaw, PhD.</u>	<u>pbs3</u>	<u>4091</u>	<u>NIOSH/DART</u>
Investigator 5	_____	_____	_____	<u>NIOSH/</u>

SEV # is CDC's Scientific Ethics Verification Number. CDC NC/Division is the national center (or equivalent) and division (or equivalent), or coordinating center or office if submitted at that level.

Continue list here of all other CDC and NIOSH investigators, if any. Include name and degrees, user ID, CDC SEV #, CDC NC/Division:

### 3 CDC's Research Partners

Research partners include *all* direct and indirect recipients of CDC funding (e.g., grants, cooperative agreements, contracts, subcontracts, purchase orders) and other CDC support (e.g., identifiable private information, supplies, products, drugs, or other tangible support) for this research activity, as well as collaborators who do not receive such support. On continuing review, HRPO needs current information on partners that have been added or dropped since the last review and partners that, as of the last review, were receiving support for nonexempt research. See *HRPO Guide: CDC's Research Partners* for further details.

All CDC partners must be listed on form CDC 0.1370.

Check one of the following.

- No research partners are reported with this submission. (Checked when there are **no** non-CDC partners.)
- Research partners (non-CDC) are listed on form CDC 0.1370, which accompanies this form.

#### 4 Study Participants—Cumulative Demographic Frequencies

Have any participants been enrolled in the last 12 months?  Yes  No (If no, still report total subject # to date.)

Report estimated counts (rather than percentages). Include participants at domestic and foreign sites. [Note: All sub-category totals should be equal; total subject numbers are counted from **beginning** of study conduct until the date completing this form. See also *HRPO Guide: IRB Review Cycle* for definitions.]

Number of Participants	76
Location of Participants	
Participating at Domestic Sites	76
Participating at Foreign Sites	_____
Sex/Gender of Participants	
Female	1
Male	75
Sex/Gender Not Available	_____
Ethnicity of Participants	
Hispanic or Latino	_____
Not Hispanic or Latino	_____
Ethnicity Not Available	76
Race of Participants	
American Indian or Alaska Native	_____
Asian	_____
Black or African American	_____
Native Hawaiian or Other Pacific Islander	_____
White	_____
More Than One Race	_____
Race Not Available	76

CDC Form 0.1250 initial review, #5 cited 125 number estimated subjects. To exceed subject # cited on CDC 0.1250, an amendment request (CDC forms 0.1252+ 0.1379) needs to be completed/submitted to the NIOSH IRB-HSRB for review/approval. Comments on Demographics:

INTERVENTIONS TO REDUCE SHOULDER MSDS IN OVERHEAD ASSEMBLY

#### 5 Study Status—Participant Involvement

##### 5.1 Contact Status

“Contact” means intervention or interaction with participants, such as recruitment, screening, obtaining consent, enrollment, and collection of data and biological specimens directly from participants. Check one of the following.

- Study is not designed to involve research-related contact with participants (e.g., research using existing records); study activities involve only access to or analysis of data or biological specimens and writing reports.
- Study is designed to involve contact with participants. Check one of the following:
  - Contact with participants has not yet begun. (If checked, include a cc current consent with submission.)
  - Contact with participants has begun and continues; this may include follow-up for debriefing or notification of results. (If checked, include a cc current consent with submission.)
  - Contact with participants is completed; study activities involve only data analysis or report writing.

## 5.2 Consent Status

“Consent” includes adult consent, child assent, and parental permission. Check one of the following.

- The IRB previously waived all requirements both to obtain and to document consent in this study.
- Although not waived, there is no further need to obtain or document consent (e.g., enrollment is complete).
- Participants will be asked to provide consent (with or without documentation).

If you check the third box, please include all current consent, assent, and parental permission materials (e.g., scripts, documents) from each study site with this submission.

## 6 Study Status—Overall Conduct [Please complete all summaries.]

Summary of research activities to date. Briefly summarize study progress and interim findings. Include the number of potential subjects who declined enrollment and the number who withdrew from the study. If this study involves a registrable clinical trial, summarize registration status. [Citing “none” for this summary is incomplete.]

In the previous year 14 participants were enrolled to bring the total to 76. We are aware of 13 participants who have formally withdrawn from the study for a number of reasons that include being transferred from the Departments under study or leaving the company.

Summary of study changes reviewed and approved since the last continuation. Do not include changes submitted with or before approval of this continuation but not yet approved.

none

Summary of any recent literature or other information relevant to the research study (not limited to information with CDC co-authorship).

none

Summary of all adverse events to date. In particular, address adverse events that were serious, unexpected (or more frequent or severe than expected), or at least possibly related to the research.

none

Summary of (a) incidents that are not adverse events and (b) other substantial concerns since last continuation.

none

List and include copies of progress or monitoring reports on safety or compliance (e.g., site monitor, safety review, DSM report, multi-center trial report, but not reports to PGO).

n/a

Summary of remaining research activities, emphasizing future contact with subjects, use of identifiable private data and biological specimens, and preparation of primary reports. [Citing “none” for this summary is incomplete.]

Investigators will continue to recruit participants, particularly in the tool support condition until 125 participant goal, as approved in the original protocol, is attained.

## 7 Regulation and Policy

### 7.1 Mode of IRB Review on CDC's Behalf

Location of IRB (Check one.):

- CDC IRB (Ex. NIOSH IRB/HSRB)  
 Non-CDC IRB through IRB Authorization Agreement [Submit form CDC 0.1371 if this is a new request.]

Institution or Organization Providing IRB Review: \_\_\_\_\_

IRB Registration Number (if known): \_\_\_\_\_

Federal-Wide Assurance Number (if any): \_\_\_\_\_

IRB-Determined Level of Risk to Subjects (Check one.):

- Minimal  
 Greater than Minimal

Suggested Level of IRB Review (Check one.):

See *HRPO Worksheet for Expedited Review* for detailed assistance. If relying on a non-CDC IRB, please indicate the level of review that you think is appropriate under human research regulations.

- Convened-board review is suggested.

Reason for Convened Review: \_\_\_\_\_

- Expedited review is suggested, under the following categories (Check all that apply.):

- 1a Study of drugs not requiring Investigational New Drug exemption from FDA  
 1b Study of medical devices not requiring Investigational Device Exemption from FDA  
 2a Collection of blood from healthy, nonpregnant adults; below volume limit, minimally invasive  
 2b Collection of blood from other adults and children; below volume limit, minimally invasive  
 3 Prospective noninvasive collection of biological specimens for research purposes  
 4 Collection of data through routine, noninvasive procedures, involving no general anesthesia, sedation, x-rays, or microwaves  
 5 Research that uses materials collected solely for nonresearch purposes  
 6 Collection of data from voice, video, digital, or image recordings made for research purposes  
 7 Research that uses interview, program evaluation, human factors, or quality assurance methods

Continuing review of research previously approved by the convened IRB (8a, 8b, 8c, or 9) where:

- 8a The research is permanently closed to the enrollment of new subjects; all subjects have completed all research-related interventions; and the research remains active only for long-term follow-up of subjects  
 8b No subjects have been enrolled and no additional risks have been identified  
 8c The remaining research activities are limited to data analysis  
 9 Continuing review of research, not under IND/IDE, where categories 2 through 8 do not apply but the IRB has determined and documented at a convened meeting that the research involves no greater than minimal risk and no additional risks have been identified

**8 Material Submitted with this Form**

Check all that apply. Describe additional material in the comments section. Required items are indicated. Optional items may be requested by HRPO or the IRB.

- Complete protocol (required if research poses more than minimal risk to subjects, is under IND/IDE, or has changed in the past 12 months)
- Consent, assent, and permission documents or scripts (required if consent will be sought in the future from prospective subjects or their representatives [see section 5.2])
- Other information for recruits or participants (e.g., ads, brochures, flyers, scripts; required if consent will be sought in the future from prospective subjects or their representatives)
- Data collection instruments (e.g., questionnaires, interview scripts, record abstraction tools; required if protocol has changes in the past 12 months)
- Certification of IRB approval or exemption for research partners (required only for partners being added or for supported/nonexempt partners)
- Progress and monitoring reports (recommended when available)

**9 Additional Comments** (Cover Memo content can go here.)



0.1370 Centers for Disease Control and Prevention

## CDC's Research Partners

Use this form to report current information on CDC's research partners whenever a partner institution or individual is added or information changes. Supply individual name and completed ethics training documentation only for investigators collaborating with CDC under an individual investigator agreement (IIA). See *HRPO Guide: CDC's Research Partners* and either the *HRPO Worksheet for Basic Tracking of Research Partners* or the *HRPO Worksheet for Advanced Tracking of Research Partners* for details on how to complete this form.

Leave protocol ID blank if not yet assigned.

CDC Protocol ID: HSRB 12-DART-04XP Protocol Version Number: \_\_\_\_\_ Version Date: \_\_\_\_\_

Protocol Title:

INTERVENTIONS TO REDUCE SHOULDER MSDS IN OVERHEAD ASSEMBLY

**NOTE:** Each partner below reflects either a non-CDC **Institution** or non-CDC **Individual** so all fields cannot be completed. At minimum, please provide the name of the Institution/Individual; their City/State; and briefly cite in the Comments field their role in this research (what they will do) and include your estimate of engaged or not. Engaged means either to: 1) interact/intervene with subjects; **or** 2) access private/identifiable information; **or** 3) receive federal funds.

### Partner 1

Institution Name: Toyota Motors Manufacturing Kentucky  
 Institution Location: Georgetown, KY  
 Individual Name (IIA only): Sean Wilson  
 Reporting Status: Initial Report  
 Regulatory Coverage: Engaged/Non-Exempt  
 Financial Support: No Financial Support  
 Support Award Number: \_\_\_\_\_  
 Support End Date: \_\_\_\_\_  
 Nonfinancial Support: No Nonfinancial Support  
 FWA Number: \_\_\_\_\_  
 SEV Number (IIA only): 1161572  
 IRB Review Status: Relying On CDC IRB  
 IRB Approval Expiration Date: \_\_\_\_\_  
 Comments (Their Role in this Research):

*1373A on file 7/1/2013*

*DCM*

### Partner 2

Institution Name: \_\_\_\_\_  
 Institution Location: \_\_\_\_\_  
 Individual Name (IIA only): \_\_\_\_\_  
 Reporting Status: \_\_\_\_\_  
 Regulatory Coverage: \_\_\_\_\_  
 Financial Support: \_\_\_\_\_  
 Support Award Number: \_\_\_\_\_  
 Support End Date: \_\_\_\_\_  
 Nonfinancial Support: \_\_\_\_\_  
 FWA Number: \_\_\_\_\_  
 SEV Number (IIA only): \_\_\_\_\_  
 IRB Review Status: \_\_\_\_\_  
 IRB Approval Expiration Date: \_\_\_\_\_  
 Comments (Their Role in this Research):



**Partner 3**

Institution Name: \_\_\_\_\_  
Institution Location: \_\_\_\_\_  
Individual Name (IIA only): \_\_\_\_\_  
Reporting Status: \_\_\_\_\_  
Regulatory Coverage: \_\_\_\_\_  
Financial Support: \_\_\_\_\_  
Support Award Number: \_\_\_\_\_  
Support End Date: \_\_\_\_\_  
Nonfinancial Support: \_\_\_\_\_  
FWA Number: \_\_\_\_\_  
SEV Number (IIA only): \_\_\_\_\_  
IRB Review Status: \_\_\_\_\_  
IRB Approval Expiration Date: \_\_\_\_\_  
Comments (Their Role in this Research): \_\_\_\_\_

**Partner 4**

Institution Name: \_\_\_\_\_  
Institution Location: \_\_\_\_\_  
Individual Name (IIA only): \_\_\_\_\_  
Reporting Status: \_\_\_\_\_  
Regulatory Coverage: \_\_\_\_\_  
Financial Support: \_\_\_\_\_  
Support Award Number: \_\_\_\_\_  
Support End Date: \_\_\_\_\_  
Nonfinancial Support: \_\_\_\_\_  
FWA Number: \_\_\_\_\_  
SEV Number (IIA only): \_\_\_\_\_  
IRB Review Status: \_\_\_\_\_  
IRB Approval Expiration Date: \_\_\_\_\_  
Comments (Their Role in this Research): \_\_\_\_\_

**Partner 5**

Institution Name: \_\_\_\_\_  
Institution Location: \_\_\_\_\_  
Individual Name (IIA only): \_\_\_\_\_  
Reporting Status: \_\_\_\_\_  
Regulatory Coverage: \_\_\_\_\_  
Financial Support: \_\_\_\_\_  
Support Award Number: \_\_\_\_\_  
Support End Date: \_\_\_\_\_  
Nonfinancial Support: \_\_\_\_\_  
FWA Number: \_\_\_\_\_  
SEV Number (IIA only): \_\_\_\_\_  
IRB Review Status: \_\_\_\_\_  
IRB Approval Expiration Date: \_\_\_\_\_  
Comments (Their Role in this Research): \_\_\_\_\_

**Partner 6**

Institution Name: \_\_\_\_\_  
Institution Location: \_\_\_\_\_  
Individual Name (IIA only): \_\_\_\_\_  
Reporting Status: \_\_\_\_\_  
Regulatory Coverage: \_\_\_\_\_  
Financial Support: \_\_\_\_\_  
Support Award Number: \_\_\_\_\_  
Support End Date: \_\_\_\_\_  
Nonfinancial Support: \_\_\_\_\_  
FWA Number: \_\_\_\_\_  
SEV Number (IIA only): \_\_\_\_\_  
IRB Review Status: \_\_\_\_\_  
IRB Approval Expiration Date: \_\_\_\_\_  
Comments (Their Role in this Research): \_\_\_\_\_

**Partner 7**

Institution Name: \_\_\_\_\_  
Institution Location: \_\_\_\_\_  
Individual Name (IIA only): \_\_\_\_\_  
Reporting Status: \_\_\_\_\_  
Regulatory Coverage: \_\_\_\_\_  
Financial Support: \_\_\_\_\_  
Support Award Number: \_\_\_\_\_  
Support End Date: \_\_\_\_\_  
Nonfinancial Support: \_\_\_\_\_  
FWA Number: \_\_\_\_\_  
SEV Number (IIA only): \_\_\_\_\_  
IRB Review Status: \_\_\_\_\_  
IRB Approval Expiration Date: \_\_\_\_\_  
Comments (Their Role in this Research): \_\_\_\_\_

**Partner 9**

Institution Name: \_\_\_\_\_  
Institution Location: \_\_\_\_\_  
Individual Name (IIA only): \_\_\_\_\_  
Reporting Status: \_\_\_\_\_  
Regulatory Coverage: \_\_\_\_\_  
Financial Support: \_\_\_\_\_  
Support Award Number: \_\_\_\_\_  
Support End Date: \_\_\_\_\_  
Nonfinancial Support: \_\_\_\_\_  
FWA Number: \_\_\_\_\_  
SEV Number (IIA only): \_\_\_\_\_  
IRB Review Status: \_\_\_\_\_  
IRB Approval Expiration Date: \_\_\_\_\_  
Comments (Their Role in this Research): \_\_\_\_\_

**Partner 8**

Institution Name: \_\_\_\_\_  
Institution Location: \_\_\_\_\_  
Individual Name (IIA only): \_\_\_\_\_  
Reporting Status: \_\_\_\_\_  
Regulatory Coverage: \_\_\_\_\_  
Financial Support: \_\_\_\_\_  
Support Award Number: \_\_\_\_\_  
Support End Date: \_\_\_\_\_  
Nonfinancial Support: \_\_\_\_\_  
FWA Number: \_\_\_\_\_  
SEV Number (IIA only): \_\_\_\_\_  
IRB Review Status: \_\_\_\_\_  
IRB Approval Expiration Date: \_\_\_\_\_  
Comments (Their Role in this Research): \_\_\_\_\_

**Partner 10**

Institution Name: \_\_\_\_\_  
Institution Location: \_\_\_\_\_  
Individual Name (IIA only): \_\_\_\_\_  
Reporting Status: \_\_\_\_\_  
Regulatory Coverage: \_\_\_\_\_  
Financial Support: \_\_\_\_\_  
Support Award Number: \_\_\_\_\_  
Support End Date: \_\_\_\_\_  
Nonfinancial Support: \_\_\_\_\_  
FWA Number: \_\_\_\_\_  
SEV Number (IIA only): \_\_\_\_\_  
IRB Review Status: \_\_\_\_\_  
IRB Approval Expiration Date: \_\_\_\_\_  
Comments (Their Role in this Research): \_\_\_\_\_



